Medicare Enrolled
Dr. Tanyanika Phillips, MD
Medical Oncology · Lancaster, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Phillips from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Phillips?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Phillips
Dr. Tanyanika Phillips is a medical oncology specialist in Lancaster, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Phillips performed 24,847 Medicare services across 1,094 unique beneficiaries.
Between the years covered by Open Payments, Dr. Phillips received a total of $999 from 27 pharmaceutical and/or device companies across 54 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Phillips is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 14% volume in CA
$999 industry payments
Medicare Practice Summary
Medicare Utilization ↗24,847
Medicare services
Top 14% in CA for medical oncology
1,094
Unique beneficiaries
$20
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~1,308 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Pembrolizumab injection (Keytruda) | 6,800 | $43 | $193 |
| Anti-nausea injection (aprepitant) | 5,980 | $1 | $6 |
| Paclitaxel chemotherapy injection | 4,173 | $0 | $0 |
| Denosumab injection (Prolia/Xgeva) | 3,240 | $18 | $83 |
| Anti-nausea injection (ondansetron/Zofran) | 1,232 | $0 | $0 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
722 | $0 | $0 |
| Pegfilgrastim injection, 0.5 mg An injection of pegfilgrastim, a medication that stimulates the production of white blood cells. This specific code applies to the brand-name drug and excludes biosimilar versions. |
348 | $78 | $346 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 301 | $3 | $13 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
257 | $14 | $93 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
228 | $2 | $9 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
220 | $120 | $606 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
155 | $108 | $481 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
125 | $72 | $341 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 110 | $131 | $604 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
102 | $12 | $81 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
90 | $31 | $134 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
81 | $151 | $672 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
73 | $59 | $295 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
59 | $1 | $4 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
58 | $56 | $269 |
| Telephone medical discussion, 5-10 minutes A phone conversation with a physician lasting between 5 and 10 minutes to discuss medical matters. |
53 | $24 | $214 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
52 | $18 | $88 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
51 | $26 | $134 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
39 | $1 | $23 |
| Telephone medical discussion, 11-20 minutes A phone conversation with a physician lasting between 11 and 20 minutes. |
38 | $45 | $341 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
35 | $12 | $69 |
| On-body injector for subcutaneous injection A device is applied to the skin to automatically deliver a medication injection under the skin. |
29 | $17 | $81 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
27 | $51 | $247 |
| Initial hospital admission, low complexity Initial hospital inpatient or observation care for a new patient involving straightforward or low-level medical decision making, with at least 40 minutes total time on the date of the encounter. |
26 | $69 | $301 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
25 | $18 | $84 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
24 | $41 | $216 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
22 | $30 | $220 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
17 | $32 | $200 |
| Hospital follow-up visit, low complexity Follow-up hospital visit for an established patient with straightforward or low-level medical decision making. The visit requires at least 25 minutes of time spent on the day of service. |
16 | $41 | $180 |
| New patient office visit, complex (60-74 min) | 13 | $179 | $821 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
13 | $109 | $474 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
13 | $2 | $9 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
1.9% high complexity
95.2% medium
2.9% routine
Industry Payment Transparency
Open Payments through 2022 ↗$999
Total received (2018-2022)
Avg $200/year across 5 years
Bottom 31% in CA for medical oncology
27
Companies
54
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$929 (93.0%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$70 (7.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2022
$169
2021
$35
2020
$104
2019
$351
2018
$340
Payments by company (2022)
Consulting
Speaking
Meals & Travel
Research
Intuitive Surgical, Inc.
$114
Takeda Pharmaceuticals U.S.A., Inc.
$33
GlaxoSmithKline, LLC.
$23
Top 3 companies account for 100.0% of 2022 payments
All-time payments by company (2018-2022) ›
PFIZER INC.
$123
Intuitive Surgical, Inc.
$114
Novartis Pharmaceuticals Corporation
$95
Amgen Inc.
$92
Janssen Biotech, Inc.
$74
TESARO, Inc.
$56
Ipsen Biopharmaceuticals, Inc
$50
Takeda Pharmaceuticals U.S.A., Inc.
$47
Bayer HealthCare Pharmaceuticals Inc.
$35
GENZYME CORPORATION
$25
Genentech USA, Inc.
$24
E.R. Squibb & Sons, L.L.C.
$23
EMD Serono, Inc.
$23
GlaxoSmithKline, LLC.
$23
Abbott Laboratories
$23
Clovis Oncology, Inc.
$19
Puma Biotechnology, Inc.
$19
Celgene Corporation
$16
Foundation Medicine, Inc.
$15
Eisai Inc.
$15
MEDIVATION FIELD SOLUTIONS LLC
$14
AstraZeneca Pharmaceuticals LP
$13
Astellas Pharma US Inc
$13
EISAI INC.
$13
Seattle Genetics, Inc.
$12
TerSera Therapeutics LLC
$12
Gilead Sciences, Inc.
$12
Top 3 companies account for 33.2% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · Bavencio · CardioMEMS HF System · DARZALEX · Da Vinci Surgical System · EVENITY · Erleada · FOUNDATIONONE · Halaven · IBRANCE · ICLUSIG · IMFINZI · INLYTA · KANJINTI · KISQALI · Kyprolis · LIBTAYO · Lenvima · NERLYNX · NINLARO · Neulasta · Nplate · OPDIVO · PROMACTA · RYDAPT · Revlimid · Rubraca · SOMATULINE DEPOT · SUTENT · Stivarga · TALZENNA · TASIGNA · TECENTRIQ · XALKORI · XTANDI · Xofigo · ZEJULA · ZOLADEX
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (93%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Medical oncologists within 10 mi
2
Per 100K population
0.0
County median income
$87,760
Nearest hospital
ANTELOPE VALLEY HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2022 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Phillips is a mixed practice specialist, with above-average Medicare volume (top 14% in CA), with low-engagement industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Phillips experienced with pembrolizumab injection (keytruda)?
Based on Medicare claims data, Dr. Phillips performed 6,800 pembrolizumab injection (keytruda) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Phillips receive payments from pharmaceutical companies?
Yes. Dr. Phillips received a total of $999 from 27 companies across 54 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Phillips's costs compare to other medical oncologists in Lancaster?
Dr. Phillips's average Medicare payment per service is $20. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Phillips) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologists in Lancaster
Browse medical oncologists in Lancaster ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in CA
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in CA
Which CA medical oncologists receive the most from drug and device companies.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
By company
Intuitive Surgical, Inc. Payments to Doctors
See all physicians who received payments from Intuitive Surgical, Inc.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology